| Reference | </br>1:Effects of levodopa/carbidopa intestinal gel versus oral levodopa/carbidopa on B vitamin levels and neuropathy. Loens S, Chorbadzhieva E, Kleimann A, Dressler D, Schrader C.Brain Behav. 2017 Apr 7;7(5):e00698. doi: 10.1002/brb3.698. eCollection 2017 May. PMID: 28523235 </br>2:Liquid levodopa-carbidopa in advanced Parkinson/’s disease with motor complications. Yang HJ, Ehm G, Kim YE, Yun JY, Lee WW, Kim A, Kim HJ, Jeon B.J Neurol Sci. 2017 Jun 15;377:6-11. doi: 10.1016/j.jns.2017.03.039. Epub 2017 Mar 23. PMID: 28477709 </br>3:Quantitation of levodopa and carbidopa in rat plasma by LC-MS/MS: The key role of ion-pairing reversed-phase chromatography. Chi J, Ling Y, Jenkins R, Li F.J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Jun 1;1054:1-9. doi: 10.1016/j.jchromb.2017.04.001. Epub 2017 Apr 3. PMID: 28412665 </br>4:The use of enteral access for continuous delivery of levodopa-carbidopa in patients with advanced Parkinson/’s disease. Cheron J, Deviere J, Supiot F, Ballarin A, Eisendrath P, Toussaint E, Huberty V, Musala C, Blero D, Lemmers A, Van Gossum A, Arvanitakis M.United European Gastroenterol J. 2017 Feb;5(1):60-68. doi: 10.1177/2050640616650804. Epub 2016 Jun 23. PMID: 28405323 Free PMC Article</br>5:Small bowel obstruction secondary to distal migration of the intestinal probe in a patient with an endoscopic gastrostomy for continuous carbidopa-levodopa infusion. Díaz Gómez A, Díaz Ruiz R, Nogales Ó, de la Casa B, Fernández Alvárez C, González Asanza C.Gastroenterol Hepatol. 2017 Apr 5. pii: S0210-5705(17)30052-3. doi: 10.1016/j.gastrohep.2017.02.007. [Epub ahead of print] English, Spanish. No abstract available. PMID: 28390797 </br>6:Delayed O-methylation of l-DOPA in MB-COMT-deficient mice after oral administration of l-DOPA and carbidopa. Tammimäki A, Aonurm-Helm A, Männistö PT.Xenobiotica. 2017 Apr 21:1-7. doi: 10.1080/00498254.2017.1315781. [Epub ahead of print] PMID: 28375049 </br>7:[Levodopa-carbidopa intestinal gel in the treatment of patients with Parkinson disease: results of a 12-month open study]. Skoromets AA, Odinak MM, Yakupov EZ, Litvinenko IV, Zalyalova ZA, Timofeeva AA, Kirtaev SY, Bogdanov RR, Agafina AS, Chatamra K, Robieson W, Benesh J, Latypova GR, Ershova MV, Illarioshkin SN.Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(2):22-31. doi: 10.17116/jnevro20171172122-31. Russian. PMID: 28374689 </br>8:Levodopa-carbidopa enteral suspension in advanced Parkinson/’s disease: clinical evidence and experience. Virhammar J, Nyholm D.Ther Adv Neurol Disord. 2017 Mar;10(3):171-187. doi: 10.1177/1756285616681280. Epub 2016 Dec 1. Review. PMID: 28344656 Free PMC Article</br>9:First clinical experience with levodopa/carbidopa microtablets in Parkinson/’s disease. Senek M, Hellström M, Albo J, Svenningsson P, Nyholm D.Acta Neurol Scand. 2017 Mar 15. doi: 10.1111/ane.12756. [Epub ahead of print] PMID: 28299787 </br>10:Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy. Espay AJ, Pagan FL, Walter BL, Morgan JC, Elmer LW, Waters CH, Agarwal P, Dhall R, Ondo WG, Klos KJ, Silver DE.Neurol Clin Pract. 2017 Feb;7(1):86-93. doi: 10.1212/CPJ.0000000000000316. Review. PMID: 28243505 Free PMC Article
|
